HUMAN ANTI INTEGRIN ALPHA 4 (NATALIZUMAB BIOSIMILAR)

Human Anti-Integrin Alpha 4 Antibody is a research grade biosimilar of the monoclonal antibody drug natalizumab. It is a recombinant human IgG4 kappa antibody with variable regions from the therapeutic antibody natalizumab. Human Anti-Integrin Alpha 4 Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-natalizumab antibodies, for example HCA248 and HCA249P. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-natalizumab antibody in IgG1 format as reference standard, for example HCA249. Natalizumab (Tysabri) is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn’s disease. Natalizumab is also being evaluated for potential clinical use in the treatment of B-cell malignancies. This therapeutic antibody, directed against alpha-4 integrin (CD49d), binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier.This product is NOT FOR THERAPEUTIC USE.View a summary of supporting anti-natalizumab antibody products

• Clonality: Monoclonal
• Host: Human
• Reactivity: Human
• Isotype: IgG4

• Quantity: 0.2 mg
• Storage: +4ºC, -20ºC if preferred
• Buffer: Phosphate buffered saline, 0.02% Proclin 300

• ELISA (ELISA)